CONFERENCE AGENDA

 

 

Singapore, 31 March 2020 - 1 April 2020

Schedule

Create your personal agenda –check the favourite icon

Mar 3111:30
Conference pass

Panel: Asia's immunotherapy landscape and lessons learned from international successes

Immunotherapy
Mar 3111:30
Conference pass

Enleofen Bio: First-in-class Therapeutics for Fibro-inflammatory Diseases

Clinical Trials
Mar 3111:30
Conference pass

Neurotech: the next frontier

Pharma 4.0
Charles Stacey, President And Chief Executive Officer, CERECINSingapore
Mar 3111:30
Conference pass

Moving from market access to patient access from a payer's perspective

Market Access & Pricing
Anand Jha, Managing Director, Ansea Consultants Pte LtdSingapore
Mar 3111:30
Conference pass

Advances in precision medicine: Role of AI

Bio Data
Rajiv Rana, Regional Medical Director Asia Pacific, Merck Pte. Ltd.Singapore
Mar 3111:30
Conference pass

Panel: Bio-Entrepreneur Journey - Trials and Tribulations on the Path to Success

Biotech Invest
Yen Choo, Associate Professor, Lee Kong Chian School of MedicineSingapore
Anthony Desir, Director, MoexaHong Kong
Mar 3111:50
Conference pass

CURATE.AI: Finding the optimal drugs and dosage

Pharma 4.0
Dean Ho, Co-Founder, KYAN TherapeuticsUnited States
Mar 3112:10
Conference pass

Humanized mouse model: A tool to address human specific questions in biomedical research

Clinical Trials
Qingfeng Chen, Principal Investigator, A-starSingapore
Mar 3112:10
Conference pass

How AI is creating opportunities for pharma

Pharma 4.0
Vikram Shetty, Country Medical Lead, PfizerSingapore
Mar 3112:10
Conference pass

Making antibodies affordable for all

Market Access & Pricing
Pritha Aggarwal, Senior Program Specialist, IAVIIndia
Mar 3114:00
Conference pass

Panel: Accessing capital for scaling up your biotech

Biotech Invest
Mar 3114:20
Conference pass

Keynote Panel: AI-driven drug discovery

Keynotes
Chris Gibson, Chief Executive Officer And Co-Founder, Recursion PharmaceuticalsUnited States
Mar 3115:40
Conference pass

PKPD considerations for T-cell dependent Bispecifics (TDBs)

Immunotherapy
Mar 3115:40
Conference pass

Moving from conventional clinical trials to adaptive clinical trials

Clinical Trials
John Patava, Chief Operating Officer, AUM BiosciencesSingapore
Mar 3115:40
Conference pass
Mar 3115:40
Conference pass

Panel: Real world evidence - Driving a new drug development paradigm

Market Access & Pricing
Mar 3116:00
Conference pass

Panel: Partnering for the next immuno-oncology breakthrough

Immunotherapy
Stefan Hart, Senior Director, Scientific Innovation Oncology, J&J Innovation CentreSingapore
Mar 3116:00
Conference pass

Challenges in development of biosimilars and biosimilarity assessment - statistical perspective

Clinical Trials
Sophie Tsou, Associate Investigator, Division Of Biostatistics And Bioinformatics, National Health Research InstitutesTaiwan
Mar 3116:00
Conference pass

Synthetic DNA technologies enable antibody discovery and optimization

Pharma 4.0
Mar 3116:00
Conference pass

Panel: Attracting early stage capital: What are VCs looking for in biotech investments in Asia?

Biotech Invest
Gavin Teo, General Partner, B Capital GroupUnited States
Rohit Pratap Singh, Vice President, Xeraya Capital Sdn BhdMalaysia
Mar 3116:20
Conference pass

Adaptive designs in early clinical studies

Clinical Trials
Vincenzo Teneggi, Senior Medical Director, EDDC, A*STARSingapore
Mar 3116:20
Conference pass

Accelerating antibody engineering and discovery using synthetic libraries

Pharma 4.0
Cedric Wu, Vice President Of R&D, GenScriptUnited States
Mar 3116:40
Conference pass

Driving immuno-oncology with rational antibody discovery

Immunotherapy
Mar 3116:40
Conference pass

Panel: Clinical trials in China

Clinical Trials
Moderator: Judith Walker, Chief Medical Officer, CERECINSingapore
Daniel Liu, Chief Scientific Officer, Beijing Clinical Service Center
Da Liu, Managing Director, China Resources Life Science FundHong Kong
Mar 3116:40
Conference pass

Integrating machine learning and combinatorial CRISPR for drug development for the precision medicine paradigm

Pharma 4.0
Jeffrey Lu, Co-Founder And Chief Executive Officer, Engine BiosciencesUnited States
Mar 3116:40
Conference pass

Forming a collaborative relationship with stakeholders and payers

Market Access & Pricing
Shailendra Bajpai, Global Head Of Disease Management And Key Stakeholder Engagement, Sanofi-Aventis Singapore Pte LtdSingapore
Mar 3117:00
Conference pass

Changing paradigms in drug discovery - combining robotics and AI

Pharma 4.0
Mar 3117:20
Conference pass

Singapore's cancer clinical trials ecosystem - Challenges and solutions for stakeholders

Clinical Trials
Mar 3117:20
Conference pass

Challenges and regulatory considerations in development of complex generics

Pharma 4.0
Mar 319:20
Conference pass

Keynote Panel: The digital opportunity for pharma - New technology, new investments, new opportunities

Keynotes

Create your personal agenda –check the favourite icon

Apr 109:20
Conference pass

Keynote Panel: Fostering innovation through partnerships

Keynotes
Anand Gautam, Senior Director And Head, External Science And Innovation, Anz And Sea, PfizerAustralia
Damian O'Connell, Chief Executive Officer Experimental Drug Development Centre, A Star - Agency For Science Technology And ResearchSingapore
Apr 111:40
Conference pass

Drug development – critical need to move beyond single agent therapy

Immunotherapy
Apr 111:40
Conference pass
Apr 111:40
Conference pass
Apr 111:40
Conference pass

Utility of AI and big data in drug development

Bio Data
Vishal Doshi, Chief Executive Officer, AUM BiosciencesSingapore
Apr 112:00
Conference pass

Panel: Partnering to improve quality in clinical trials

Clinical Trials
Sunil Pandita, Manager Clinical Quality Assurance, Abbott LabSingapore
Arani Chatterjee, Senior Vice President, Clinical Research, Aurobindo PharmaIndia
Hyejin Shin, Director, Group Leader, Clinical Qa, Samsung BioepisRepublic Of Korea
Apr 112:00
Conference pass

Panel: Partnering for the future

Pharma 4.0
James Garner, Chief Executive Officer And Managing Director, Kazia Therapeutics LimitedAustralia
Apr 114:00
Conference pass

The progression of Car-T Therapy in clinical settings

Immunotherapy
Aung Myo, Vice President, Clinical Development, Tessa TherapeuticsSingapore
Apr 114:00
Conference pass

Improving patient engagement with digital therapeutics

Pharma 4.0
Apr 114:00
Conference pass

Panel: Fostering homegrown innovation in Southeast Asia - investor & biotech perspectives

Biotech Invest
Moderator: Ogan Gurel, Chief Scientific Officer, Frt, Chief Marketing Officer, Eidware, Soundmind And Visiting Professor, D.G.I.S.T.Republic Of Korea
Apr 114:20
Conference pass

LioCyx™ : Cell therapy in Asia – Current and future plans

Immunotherapy
Stephen Lim, CEO, Lion TCR Pte LtdSingapore
Apr 114:20
Conference pass
Apr 114:20
Conference pass

Panel: Using digital therapeutics to drive innovation

Pharma 4.0
Moderator: Evelyn Pang, Manager, L.E.K. ConsultingSingapore
Apr 114:40
Conference pass

Application of NK cell and T cell therapy for the treatment of cancer

Immunotherapy
Sarmistha Deb, Chief Scientific Officer, DiponEd BioIntelligenceIndia
Apr 115:00
Conference pass

Global industry adopted clinical project management competencies

Clinical Trials
Apr 115:00
Conference pass

How technology is creating new opportunities for patient centricity

Pharma 4.0
Khee Suan Bang, Clinical Study Manager, Digital And Real-World Evidence, Danone Nutricia ResearchSingapore
Apr 115:20
Conference pass

Panel: The future of clinical trials in Asia

Clinical Trials
Apr 115:20
Conference pass

Personalised Healthcare - Building the next frontier today

Pharma 4.0
Jek Fong, Head Of Market Access, RocheSingapore
Apr 115:40
Conference pass

How innovation is driving patient centricity: Japan and other perspectives

Pharma 4.0
last published: 13/Jan/20 08:05 GMT

 

 

 

DOWNLOAD PROSPECTUS

 

 

For speaking, sponsorship and exhibition opportunities contact jonathan.mottram@terrapinn.com
Tel: +65 6322 2738